3. Syndeio Biosciences: Repairing synapses for brain health
Launched in 2025 and headquartered in Indianapolis, Indiana, Syndeio Biosciences is pioneering neurotherapeutics that target synaptic dysfunction in central nervous system (CNS) disorders like Alzheimer’s disease and depression. Their approach involves small molecules that enhance synaptic health, restoring neural connections impaired in “synaptopathies.” This precision medicine strategy aims to treat root causes rather than symptoms, drawing from advanced neuroscience research.
In a blockbuster debut, Syndeio emerged in May 2025 with over $90 million in funding from investors including Innoviva, Catalio Capital Management, and others. This capital supports their lead programs into clinical trials, focusing on Alzheimer’s and major depressive disorder. The company’s launch has generated buzz for its potential to fill gaps in CNS treatments, where current drugs often fail to halt progression.
Why watch? With the global CNS disorder market projected to exceed $130 billion by 2030, Syndeio’s synapse-targeted platform could disrupt entrenched players. Their rapid funding success signals strong investor confidence in 2025 breakthroughs.
4. BiomEdit: Microbiome innovation for animal health
Fishers/Greenfield-based BiomEdit, founded in 2022, engineers microbiome-based solutions to improve animal health and sustainability in agriculture. Their designer probiotics combat diseases in livestock, such as enteric infections in pigs and poultry, using synthetic biology to create targeted microbial therapeutics. This reduces antibiotic reliance, addressing antimicrobial resistance, a growing global concern.
In July 2025, BiomEdit closed an oversubscribed $18 million Series B with participation from Nutreco and Betagro Ventures. The funding advances their lead product, BE-10, into the final development phases. They’ve also secured USDA grants for biologics against Highly Pathogenic Avian Influenza.
Why watch? As food security and sustainable farming rise on agendas, BiomEdit’s platform could expand to human health applications, positioning Indiana as a leader in ag-biotech crossovers.
5. Modicus Prime: AI-driven quality control in biomanufacturing
Established in 2020 in La Porte, Modicus Prime is advancing AI software to automate biologics image analysis for pharmaceutical quality control. Their GxP-compatible platform enables real-time detection of contaminants and anomalies in manufacturing processes, reducing costs by up to 50-60x and preventing drug product failures. The company empowers biotech experts with self-service AI tools for in-house analysis.
Modicus Prime has raised over $3.5 million in total funding. In July 2024, they announced residency at Johnson & Johnson Innovation — JLABS @ TMC to accelerate commercialization. As of 2025, the company launched an AI image processing add-on in collaboration with eLabNext, enhancing electronic lab notebooks for life sciences workflows.
Why watch? With AI revolutionizing biopharma, Modicus Prime’s solutions address critical quality assurance gaps, potentially leading to strategic partnerships and expansions in 2025.
The bright future of Indiana’s life science industry
These startups exemplify Indiana’s vibrant life sciences landscape, where innovation meets investment to tackle pressing health issues. As they advance through clinical stages and commercialization in 2025, keep an eye on potential IPOs, acquisitions, and global impacts. With the state’s supportive infrastructure, the future looks bright for Indiana biotech.